Investor Relations
Welcome to the Investor Relations for Phase Holographic Imaging (PHI)
What’s New
Press Releases
News featuring PHI
About PHI
Phase Holographic Imaging (PHI) develops and markets its non-invasive time-lapse imaging instruments. The company’s current HoloMonitor® products are globally used for long-term quantitative analysis of living cell cultures, particularly in preclinical research.
Now, PHI is actively focusing on business development. With unique solutions focused on Quantitative Phase Imaging (QPI) — a technology that brings a novel, cell-friendly approach to critical cell quality evaluation, PHI is expanding into the fast-growing regenerative medicine field.
PHI envisions transforming live cell analysis and establishing its QPI technology as a standard for cell quality control, making our future cell therapies safe, affordable, and accessible for patients. PHI is based in Lund, Sweden, Boston, MA and Winston-Salem, NC.
July 2024 Interview with PHI AB — Step inside our headquarters and meet the team!
Finwire Media interviewed us about our current business and future outlook in regenerative medicine. How are we shaping the future of scientific research and cell therapy quality control with our innovative live cell analysis technology? How are we positioned to reach profitability, and why do investors take a closer look at PHI?
Investor Information
All Press Releases
Here you can read all PHI press releases.
Company News
Here you see PHI featured in news and CEO commentaries.
Reports & Documents
Here you find PHI’s interim and annual reports, as well as view general meeting and emission documents.
Investor Q&A
Here you can browse the frequently asked investor questions and quickly find your answers.
Any questions? Please get in touch with our CEO,
Anders Månsson, at: ir@phiab.com
Investor Calendar
Annual General Meeting
January 8, 2025
Interim Report 3 2024/25
March 13, 2025
Stock Information
The PHI stock is listed on the Spotlight Stock Market,
a Multilateral Trading Facility (MTF).
Since August 15th, 2024, PHI has also been dual-listed on the US-based OTCQB Venture Market.
Thank you to our investor community for sharing our vision, and believing in the company and the impact our products and technology have on advancing research within life science and the future of medicine.